Europska Unija - hrvatski - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - budesonid / formoterol teva pharma b. je indiciran u odrasloj dobi od 18 godina i stariji. asthmabudesonide/Формотерола tewa pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Europska Unija - hrvatski - EMA (European Medicines Agency)

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Europska Unija - hrvatski - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (stranice 123i) - radionuclide imaging; dementia; movement disorders - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. kod odraslih pacijenata, kako bi razlikovati vjerojatno demencije s тельцами levy od alzheimerove bolesti .  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

g.l. pharma gmbh, schlossplatz 1, lannach, austrija - tapentadoltartarat - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 100 mg tapentadola (u obliku tapentadoltartarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

g.l. pharma gmbh, schlossplatz 1, lannach, austrija - tapentadoltartarat - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 150 mg tapentadola (u obliku tapentadoltartarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

g.l. pharma gmbh, schlossplatz 1, lannach, austrija - tapentadoltartarat - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 200 mg tapentadola (u obliku tapentadoltartarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

g.l. pharma gmbh, schlossplatz 1, lannach, austrija - tapentadoltartarat - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 25 mg tapentadola (u obliku tapentadoltartarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

g.l. pharma gmbh, schlossplatz 1, lannach, austrija - tapentadoltartarat - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 250 mg tapentadola (u obliku tapentadoltartarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

g.l. pharma gmbh, schlossplatz 1, lannach, austrija - tapentadoltartarat - tableta s produljenim oslobađanjem - urbroj: jedna tableta s produljenim oslobađanjem sadrži 50 mg tapentadola (u obliku tapentadoltartarata)